John Kilhefner

John Kilhefner

John Kilhefner is Senior Managing Editor of the Luke Lango franchise, which includes Hypergrowth Investing, Innovation Investor, Crypto Investor Network, and more.
Kilhefner has contributed to media such as Benzinga, The Hill, Tip Ranks, Unwinnable, The Arcade Review, Five Out of Ten magazine, and ZAM. He has appeared in U.S. News and World Report, Kotaku, USA Today, and Game Developer.
He now runs his own creative agency focused on tech and cybersecurity, called Skellator, LLC.
Learn more here

Recent Articles

Alphabet Inc (GOOG) Stock: Q2 Expectations Are WAY Too High!

Alphabet Inc (GOOG) stock may not do so hot this quarter, but it could see a huge margin increase over the next few years.

Fitbit Inc: Why FIT Stock Has This Analyst Bearish

Piper Jaffray analysts trimmed their price target on Fitbit stock, which sent FIT shares on a roller coaster ride Tuesday afternoon.

Stone Energy Corporation: SGY Stock Has Gotten TOO Hot

Stone Energy (SGY) stock has been unstoppable lately, but the 300%-plus gains over the past month may be a bit too enthusiastic.

Kinder Morgan Inc (KMI) Agrees to $1.47B Deal With Southern Co (SO)

Kinder Morgan and Southern Co agreed to a huge deal that allows the two to work on the SNG pipeline while KMI reduces its debt load.

GoPro Inc (GPRO): GoPro Stock Pops 12% on … Pokemon Go?

GoPro is surging by double digits on Monday on simple rumors and tangential news. GPRO stock might look like a better speculative bet, but it's still a speculative bet.

Box Office Recap: ‘The Secret Life of Pets’ Dominates

The summer box office is going to have a hard time keeping up with last summer, but thanks to "The Secret Life of Pets" and a few holdovers, the numbers came in stronger than expected.

TWTR Stock: Twitter Inc Live Sports Debuts With Wimbledon

Twitter (TWTR) just gave the world its first glimpse of live sports streaming with Wimbledon and a little help from ESPN.

Apple Inc.: The Brexit Vote Could Put a Hurting on AAPL Stock

Citgroup analysts lowered their estimates on Apple (AAPL) stock, citing the Brexit vote as a factor affecting earnings. Should you still buy?

Insys Therapeutics Inc: FDA Approval of Syndros Sends INSY Stock SOARING

INSY is flying high after posting 9% gains on the strength of Insys Therapeutics' now-FDA-approved drug, Syndros.

Netflix Stock Pops 5% on Nothing But Chatter (NFLX)

Netflix stock is cruising on ... well, nothing but rumors on Chinese expansion and a Disney buyout. The former, at least, has a little basis in reality.